[Interferon therapy in multiple myeloma].
Multiple myeloma is a B-cell malignancy characterised by a clonal expansion of plasma cells. Prognosis of the disease can be based upon clinical stage and biological features of myeloma cells as well as of their products. Cytostatic therapy is a standard in the treatment of multiple myeloma. A new aspect is the therapeutic administration of recombinant interferons (rIFNs). Some experience has been gathered that chemotherapy-induced remissions (plateau phase) can be maintained by IFN-therapy. In induction therapy, IFN in combination with cytostatic agents has some therapeutical relevance, either. The administration of IFN in the treatment of multiple myeloma represents a new therapeutic strategy.
Micksche
M
M
Abteilung für Agewandte und Experimentelle Onkologie, Universität Wien.
D014408:Biomarkers, Tumor / Q000097:blood; D003131:Combined Modality Therapy; D006801:Humans; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D009101:Multiple Myeloma / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D011379:Prognosis
D014408:Biomarkers, Tumor; D016898:Interferon-alpha
Interferontherapie beim multiplen Myelom.